# Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Glabellar Lines

> **NCT04143815** · PHASE2 · COMPLETED · sponsor: **Medy-Tox** · enrollment: 200 (actual)

## Conditions studied

- Glabellar Frown Lines

## Interventions

- **DRUG:** MBA-P01 (Botulinum toxin A)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04143815
- **Lead sponsor:** Medy-Tox
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-20
- **Primary completion:** 2020-09-01
- **Final completion:** 2020-09-01
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2021-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04143815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04143815, "Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Glabellar Lines". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04143815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*